Phase 1 Study of Anti-Glycation Agent GLY-230 in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Glycadia
ClinicalTrials.gov Identifier:
NCT00544921
First received: October 15, 2007
Last updated: NA
Last verified: October 2007
History: No changes posted

October 15, 2007
October 15, 2007
October 2005
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Phase 1 Study of Anti-Glycation Agent GLY-230 in Healthy Subjects
Phase 1 Study of Anti-Glycation Agent GLY-230

To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.

Not Provided
Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Diabetes
Drug: GLY-230
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
54
September 2006
Not Provided

Inclusion Criteria:

  • Men age 18-55
  • Negative drug screen
  • Normal EKG, clinical chemistries, CBC, urinalysis, and
  • Give written informed consent

Exclusion Criteria:

  • Active concomitant serious medical or surgical disease,
  • Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days
Male
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00544921
GLY-001
No
Not Provided
Glycadia
Not Provided
Principal Investigator: Laurence Kennedy Univ. FLA Gainesville
Glycadia
October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP